O	0	11	Angiotensin
O	12	14	II
O	14	15	-
O	15	23	Receptor
O	24	34	Inhibition
O	35	39	With
B-intervention	40	51	Candesartan
O	52	54	to
O	55	62	Prevent
B-condition	63	74	Trastuzumab
I-condition	74	75	-
I-condition	75	82	Related
I-condition	83	94	Cardiotoxic
I-condition	95	102	Effects
O	103	105	in
B-eligibility	106	114	Patients
I-eligibility	115	119	With
I-eligibility	120	125	Early
I-eligibility	126	132	Breast
I-eligibility	133	139	Cancer
O	139	140	:
O	141	142	A
O	143	153	Randomized
O	154	162	Clinical
O	163	168	Trial
O	168	169	.

O	170	174	This
O	175	177	is
O	178	181	the
O	182	187	first
O	188	198	randomized
O	199	206	placebo
O	206	207	-
O	207	217	controlled
O	218	228	evaluation
O	229	231	of
O	232	233	a
O	234	241	medical
O	242	254	intervention
O	255	258	for
O	259	262	the
O	263	273	prevention
O	274	276	of
O	277	288	trastuzumab
O	288	289	-
O	289	296	related
O	297	308	cardiotoxic
O	309	316	effects
O	316	317	.

O	318	320	To
O	321	330	determine
O	331	333	as
O	334	337	the
O	338	345	primary
O	346	349	end
O	350	355	point
O	356	363	whether
O	364	375	angiotensin
O	376	378	II
O	379	389	antagonist
O	390	399	treatment
O	400	404	with
O	405	416	candesartan
O	417	420	can
O	421	428	prevent
O	429	431	or
O	432	442	ameliorate
O	443	454	trastuzumab
O	454	455	-
O	455	462	related
O	463	474	cardiotoxic
O	475	482	effects
O	482	483	,
O	484	491	defined
O	492	494	as
O	495	496	a
B-outcome-Measure	497	504	decline
I-outcome-Measure	505	507	in
I-outcome-Measure	508	512	left
I-outcome-Measure	513	524	ventricular
I-outcome-Measure	525	533	ejection
I-outcome-Measure	534	542	fraction
I-outcome-Measure	543	544	(
I-outcome-Measure	544	548	LVEF
I-outcome-Measure	548	549	)
I-outcome-Measure	550	552	of
I-outcome-Measure	553	557	more
I-outcome-Measure	558	562	than
I-outcome-Measure	563	565	15
I-outcome-Measure	565	566	%
I-outcome-Measure	567	569	or
I-outcome-Measure	570	571	a
I-outcome-Measure	572	580	decrease
I-outcome-Measure	581	586	below
I-outcome-Measure	587	590	the
I-outcome-Measure	591	599	absolute
I-outcome-Measure	600	605	value
I-outcome-Measure	606	608	45
I-outcome-Measure	608	609	%
O	609	610	.

O	611	615	This
O	616	626	randomized
O	626	627	,
O	628	635	placebo
O	635	636	-
O	636	646	controlled
O	647	655	clinical
O	656	661	study
O	662	665	was
O	666	675	conducted
O	676	683	between
O	684	691	October
O	692	696	2007
O	697	700	and
O	701	708	October
O	709	713	2011
O	714	716	in
O	717	719	19
O	720	729	hospitals
O	730	732	in
O	733	736	the
B-location	737	748	Netherlands
O	748	749	,
O	750	759	enrolling
B-total-participants	760	763	210
B-eligibility	764	769	women
I-eligibility	770	774	with
I-eligibility	775	780	early
I-eligibility	781	787	breast
I-eligibility	788	794	cancer
I-eligibility	795	802	testing
I-eligibility	803	811	positive
I-eligibility	812	815	for
I-eligibility	816	821	human
I-eligibility	822	831	epidermal
I-eligibility	832	838	growth
I-eligibility	839	845	factor
I-eligibility	846	854	receptor
I-eligibility	855	856	2
I-eligibility	857	858	(
I-eligibility	858	862	HER2
I-eligibility	862	863	)
I-eligibility	864	867	who
I-eligibility	868	872	were
I-eligibility	873	878	being
I-eligibility	879	889	considered
I-eligibility	890	893	for
I-eligibility	894	902	adjuvant
I-eligibility	903	911	systemic
I-eligibility	912	921	treatment
I-eligibility	922	926	with
I-eligibility	927	940	anthracycline
I-eligibility	940	941	-
I-eligibility	941	951	containing
I-eligibility	952	964	chemotherapy
I-eligibility	965	973	followed
I-eligibility	974	976	by
I-eligibility	977	988	trastuzumab
O	988	989	.

O	990	991	A
O	992	997	total
O	998	1000	of
O	1001	1003	78
O	1004	1009	weeks
O	1010	1012	of
O	1013	1024	candesartan
O	1025	1026	(
O	1026	1028	32
O	1029	1031	mg
O	1031	1032	/
O	1032	1033	d
O	1033	1034	)
O	1035	1037	or
B-control	1038	1045	placebo
O	1046	1055	treatment
O	1055	1056	;
O	1057	1062	study
O	1063	1072	treatment
O	1073	1080	started
O	1081	1083	at
O	1084	1087	the
O	1088	1092	same
O	1093	1096	day
O	1097	1099	as
O	1100	1103	the
O	1104	1109	first
O	1110	1121	trastuzumab
O	1122	1136	administration
O	1137	1140	and
O	1141	1150	continued
O	1151	1156	until
O	1157	1159	26
O	1160	1165	weeks
O	1166	1171	after
O	1172	1182	completion
O	1183	1185	of
O	1186	1197	trastuzumab
O	1198	1207	treatment
O	1207	1208	.

O	1209	1212	The
O	1213	1220	primary
O	1221	1228	outcome
O	1229	1232	was
B-outcome-Measure	1233	1237	LVEF
O	1237	1238	.

O	1239	1248	Secondary
O	1249	1252	end
O	1253	1259	points
O	1260	1268	included
B-outcome-Measure	1269	1276	whether
I-outcome-Measure	1277	1280	the
I-outcome-Measure	1281	1282	N
I-outcome-Measure	1282	1283	-
I-outcome-Measure	1283	1291	terminal
I-outcome-Measure	1292	1294	of
I-outcome-Measure	1295	1298	the
I-outcome-Measure	1299	1309	prohormone
I-outcome-Measure	1310	1315	brain
I-outcome-Measure	1316	1327	natriuretic
I-outcome-Measure	1328	1335	peptide
I-outcome-Measure	1336	1337	(
I-outcome-Measure	1337	1339	NT
I-outcome-Measure	1339	1340	-
I-outcome-Measure	1340	1346	proBNP
I-outcome-Measure	1346	1347	)
I-outcome-Measure	1348	1351	and
I-outcome-Measure	1352	1356	high
I-outcome-Measure	1356	1357	-
I-outcome-Measure	1357	1368	sensitivity
I-outcome-Measure	1369	1377	troponin
I-outcome-Measure	1378	1379	T
I-outcome-Measure	1380	1381	(
I-outcome-Measure	1381	1383	hs
I-outcome-Measure	1383	1384	-
I-outcome-Measure	1384	1387	TnT
I-outcome-Measure	1387	1388	)
I-outcome-Measure	1389	1392	can
I-outcome-Measure	1393	1395	be
I-outcome-Measure	1396	1400	used
I-outcome-Measure	1401	1403	as
I-outcome-Measure	1404	1413	surrogate
I-outcome-Measure	1414	1421	markers
O	1422	1425	and
B-outcome-Measure	1426	1433	whether
I-outcome-Measure	1434	1441	genetic
I-outcome-Measure	1442	1453	variability
I-outcome-Measure	1454	1456	in
I-outcome-Measure	1457	1465	germline
I-outcome-Measure	1466	1471	ERBB2
I-outcome-Measure	1472	1473	(
I-outcome-Measure	1473	1481	formerly
I-outcome-Measure	1482	1486	HER2
I-outcome-Measure	1487	1489	or
I-outcome-Measure	1490	1494	HER2
I-outcome-Measure	1494	1495	/
I-outcome-Measure	1495	1498	neu
I-outcome-Measure	1498	1499	)
I-outcome-Measure	1500	1510	correlates
I-outcome-Measure	1511	1515	with
I-outcome-Measure	1516	1527	trastuzumab
I-outcome-Measure	1527	1528	-
I-outcome-Measure	1528	1535	related
I-outcome-Measure	1536	1547	cardiotoxic
I-outcome-Measure	1548	1555	effects
O	1555	1556	.

O	1557	1558	A
O	1559	1564	total
O	1565	1567	of
B-total-participants	1568	1571	206
O	1572	1584	participants
O	1585	1589	were
O	1590	1599	evaluable
O	1600	1601	(
O	1601	1605	mean
O	1606	1609	age
O	1609	1610	,
B-age	1611	1613	49
I-age	1614	1619	years
O	1619	1620	;
O	1621	1624	age
O	1625	1630	range
O	1630	1631	,
B-age	1632	1634	25
I-age	1634	1635	-
I-age	1635	1637	69
I-age	1638	1643	years
O	1643	1644	)
B-intervention-participants	1645	1648	103
O	1649	1651	in
O	1652	1655	the
O	1656	1667	candesartan
O	1668	1673	group
O	1674	1675	(
O	1675	1679	mean
O	1680	1683	age
O	1683	1684	,
B-age	1685	1687	50
I-age	1688	1693	years
O	1693	1694	;
O	1695	1698	age
O	1699	1704	range
O	1704	1705	,
B-age	1706	1708	25
I-age	1708	1709	-
I-age	1709	1711	69
I-age	1712	1717	years
O	1717	1718	)
O	1719	1722	and
B-control-participants	1723	1726	103
O	1727	1729	in
O	1730	1733	the
O	1734	1741	placebo
O	1742	1747	group
O	1748	1749	(
O	1749	1753	mean
O	1754	1757	age
O	1757	1758	,
B-age	1759	1761	50
I-age	1762	1767	years
O	1767	1768	;
O	1769	1772	age
O	1773	1778	range
O	1778	1779	,
B-age	1780	1782	30
I-age	1782	1783	-
I-age	1783	1785	67
I-age	1786	1791	years
O	1791	1792	)
O	1792	1793	.

O	1794	1796	Of
O	1797	1802	these
O	1802	1803	,
O	1804	1806	36
O	1807	1817	manifested
O	1818	1820	at
O	1821	1826	least
O	1827	1828	1
O	1829	1831	of
O	1832	1835	the
O	1836	1837	2
O	1838	1845	primary
O	1846	1853	cardiac
O	1854	1857	end
O	1858	1864	points
O	1864	1865	.

O	1866	1871	There
O	1872	1876	were
O	1877	1878	3
O	1878	1879	.
O	1879	1880	8
O	1880	1881	%
O	1882	1886	more
B-outcome	1887	1894	cardiac
I-outcome	1895	1901	events
O	1902	1904	in
O	1905	1908	the
O	1909	1920	candesartan
O	1921	1926	group
O	1927	1931	than
O	1932	1934	in
O	1935	1938	the
O	1939	1946	placebo
O	1947	1952	group
O	1953	1954	(
O	1954	1956	95
O	1956	1957	%
O	1958	1960	CI
O	1960	1961	,
O	1962	1963	-
O	1963	1964	7
O	1964	1965	%
O	1966	1968	to
O	1969	1971	15
O	1971	1972	%
O	1972	1973	;
O	1974	1975	P
O	1976	1977	=
O	1978	1979	.
O	1979	1981	58
O	1981	1982	)
O	1982	1983	:
B-iv-bin-abs	1984	1986	20
O	1987	1993	events
O	1994	1995	(
B-iv-bin-percent	1995	1997	19
I-iv-bin-percent	1997	1998	%
O	1998	1999	)
O	2000	2003	and
B-cv-bin-abs	2004	2006	16
O	2007	2013	events
O	2014	2015	(
B-cv-bin-percent	2015	2017	16
I-cv-bin-percent	2017	2018	%
O	2018	2019	)
O	2019	2020	,
O	2021	2033	respectively
O	2033	2034	.

O	2035	2038	The
B-outcome	2039	2040	2
I-outcome	2040	2041	-
I-outcome	2041	2045	year
I-outcome	2046	2056	cumulative
I-outcome	2057	2066	incidence
I-outcome	2067	2069	of
I-outcome	2070	2077	cardiac
I-outcome	2078	2084	events
O	2085	2088	was
B-iv-bin-abs	2089	2090	0
I-iv-bin-abs	2090	2091	.
I-iv-bin-abs	2091	2093	28
O	2094	2095	(
O	2095	2097	95
O	2097	2098	%
O	2099	2101	CI
O	2101	2102	,
O	2103	2104	0
O	2104	2105	.
O	2105	2107	13
O	2107	2108	-
O	2108	2109	0
O	2109	2110	.
O	2110	2112	40
O	2112	2113	)
O	2114	2116	in
O	2117	2120	the
O	2121	2132	candesartan
O	2133	2138	group
O	2139	2142	and
B-cv-bin-abs	2143	2144	0
I-cv-bin-abs	2144	2145	.
I-cv-bin-abs	2145	2147	16
O	2148	2149	(
O	2149	2151	95
O	2151	2152	%
O	2153	2155	CI
O	2155	2156	,
O	2157	2158	0
O	2158	2159	.
O	2159	2161	08
O	2161	2162	-
O	2162	2163	0
O	2163	2164	.
O	2164	2166	22
O	2166	2167	)
O	2168	2170	in
O	2171	2174	the
O	2175	2182	placebo
O	2183	2188	group
O	2189	2190	(
O	2190	2191	P
O	2192	2193	=
O	2194	2195	.
O	2195	2197	56
O	2197	2198	)
O	2198	2199	.

O	2200	2211	Candesartan
O	2212	2215	did
O	2216	2219	not
O	2220	2226	affect
B-outcome	2227	2234	changes
I-outcome	2235	2237	in
I-outcome	2238	2240	NT
I-outcome	2240	2241	-
I-outcome	2241	2247	proBNP
I-outcome	2248	2251	and
I-outcome	2252	2254	hs
I-outcome	2254	2255	-
I-outcome	2255	2258	TnT
I-outcome	2259	2265	values
O	2265	2266	,
O	2267	2270	and
O	2271	2276	these
O	2277	2287	biomarkers
O	2288	2292	were
O	2293	2296	not
O	2297	2307	associated
O	2308	2312	with
O	2313	2324	significant
O	2325	2332	changes
O	2333	2335	in
O	2336	2340	LVEF
O	2340	2341	.

O	2342	2345	The
O	2346	2356	Ala1170Pro
O	2357	2367	homozygous
O	2368	2373	ERBB2
O	2374	2382	genotype
O	2383	2386	was
O	2387	2397	associated
O	2398	2402	with
O	2403	2404	a
O	2405	2410	lower
O	2411	2421	likelihood
O	2422	2424	of
O	2425	2428	the
O	2429	2439	occurrence
O	2440	2442	of
O	2443	2444	a
O	2445	2452	cardiac
O	2453	2458	event
O	2459	2467	compared
O	2468	2472	with
O	2473	2476	Pro
O	2476	2477	/
O	2477	2480	Pro
O	2481	2482	+
O	2483	2486	Ala
O	2486	2487	/
O	2487	2490	Pro
O	2491	2500	genotypes
O	2501	2503	in
O	2504	2516	multivariate
O	2517	2525	analysis
O	2526	2527	(
O	2527	2531	odds
O	2532	2537	ratio
O	2537	2538	,
O	2539	2540	0
O	2540	2541	.
O	2541	2543	09
O	2543	2544	;
O	2545	2547	95
O	2547	2548	%
O	2549	2551	CI
O	2551	2552	,
O	2553	2554	0
O	2554	2555	.
O	2555	2557	02
O	2557	2558	-
O	2558	2559	0
O	2559	2560	.
O	2560	2562	45
O	2562	2563	;
O	2564	2565	P
O	2566	2567	=
O	2568	2569	.
O	2569	2572	003
O	2572	2573	)
O	2573	2574	.

O	2575	2578	The
O	2579	2587	findings
O	2588	2590	do
O	2591	2594	not
O	2595	2602	support
O	2603	2606	the
O	2607	2617	hypothesis
O	2618	2622	that
O	2623	2634	concomitant
O	2635	2638	use
O	2639	2641	of
O	2642	2653	candesartan
O	2654	2662	protects
O	2663	2670	against
O	2671	2672	a
O	2673	2681	decrease
O	2682	2684	in
B-outcome	2685	2689	left
I-outcome	2690	2701	ventricular
I-outcome	2702	2710	ejection
I-outcome	2711	2719	fraction
O	2720	2726	during
O	2727	2729	or
O	2730	2737	shortly
O	2738	2743	after
O	2744	2755	trastuzumab
O	2756	2765	treatment
O	2766	2768	in
O	2769	2774	early
O	2775	2781	breast
O	2782	2788	cancer
O	2788	2789	.

O	2790	2793	The
O	2794	2799	ERBB2
O	2800	2808	germline
O	2809	2819	Ala1170Pro
O	2820	2826	single
O	2827	2837	nucleotide
O	2838	2850	polymorphism
O	2851	2854	may
O	2855	2857	be
O	2858	2862	used
O	2863	2865	to
O	2866	2874	identify
O	2875	2883	patients
O	2884	2887	who
O	2888	2891	are
O	2892	2894	at
O	2895	2904	increased
O	2905	2909	risk
O	2910	2912	of
O	2913	2924	trastuzumab
O	2924	2925	-
O	2925	2932	related
O	2933	2944	cardiotoxic
O	2945	2952	effects
O	2952	2953	.
O	2954	2968	clinicaltrials
O	2968	2969	.
O	2969	2972	gov
O	2973	2983	Identifier
O	2983	2984	:
O	2985	2996	NCT00459771
O	2996	2997	.
